Acme United Q2 2026 Earnings Beat on MyMedic Acquisition and Margin Expansion

• Acme United reported Q2 2026 EPS of $1.22, significantly beating the $0.81 consensus estimate by 50.62%.
• Revenue surged 16% year-over-year to $62.7 million, driven largely by the integration of MyMedic.
• Gross margins expanded to 42.6% from 41.0% in the prior year period, signaling improved operational efficiency.
• Management anticipates continued margin recovery as lower-cost inventory replaces higher-tariff stock by year-end.

Acme United Corporation delivered robust second-quarter 2026 financial results, significantly outperforming analyst expectations across key metrics. Earnings per share reached $1.22, surpassing the consensus forecast of $0.81 by a substantial margin. This performance was accompanied by a 16% year-over-year increase in sales, which totaled $62.72 million against estimates of $58.08 million. The stock market responded positively to the news, with shares surging approximately 11.92% to 17.52% following the earnings release. The primary driver of this growth was the recent acquisition of MyMedic, which contributed significantly to the top-line expansion. Excluding the impact of acquisitions, organic growth stood at a solid 8%, indicating underlying strength in the company's core operations.

How Did the MyMedic Acquisition Impact Growth?

The acquisition of MyMedic has become a central pillar of Acme United's growth strategy, fundamentally altering the company's revenue trajectory. The integration of this asset was the primary contributor to the 16% year-over-year sales increase reported in the second quarter. While organic growth excluding the acquisition was measured at 8%, the combined effect has created a more diversified revenue stream. Management is actively focusing on expanding the distribution of MyMedic products beyond its direct-to-consumer channels. Strategic efforts are underway to introduce these products into mass retail markets, a move expected to unlock new customer bases and drive higher volume sales. This expansion is projected to yield strong profitability in the fourth quarter, supported by typical seasonal demand patterns for medical and safety products.

What Drives the Margin Expansion and Future Outlook?

A key highlight of the quarter was the expansion of gross margins to 42.6%, an improvement from 41.0% in the same period last year. This expansion indicates improved operational efficiency and a favorable product mix within the company's portfolio. CEO Johnsen attributed this improvement to strategic pricing actions and operational adjustments. Looking ahead, management expects this margin recovery to continue throughout the remainder of the year. The company is currently transitioning from higher-tariff inventory to lower-cost stock, a process expected to persist through the end of 2026. This transition is anticipated to ease recent tariff pressures and further support profitability. The gradual replacement of inventory is a critical factor in maintaining the improved margin trajectory, as it reduces the cost of goods sold relative to revenue.

Despite the positive results, investors should remain aware of several key risks that could impact future performance. Selling, general, and administrative expenses remain elevated at 32% of sales, which may pressure net income in the near term. The company continues to face headwinds from tariff and freight costs, which could fluctuate and impact margins. Currency volatility also presents a risk, particularly given the uneven geographic performance observed during the quarter. Canada, for instance, has lagged behind other regions, indicating potential regional disparities in demand or execution. These factors underscore the importance of monitoring operational expenses and macroeconomic conditions as the company navigates its growth phase.

The integration of MyMedic and the strategic focus on mass retail distribution represent significant opportunities for long-term growth. However, the high SG&A expenses and ongoing tariff challenges require careful management to sustain the margin improvements seen in Q2. Investors should watch for updates on the integration progress and the effectiveness of the inventory transition strategy in upcoming reports. The company's ability to manage these risks while capitalizing on seasonal demand will be crucial for maintaining its upward trajectory.